Yearly Archives: 2021

Novavax (NVAX-$205.59, NASDAQ) Sold on Competitor Developments.

Today, the entire position on NVAX has been sold. Moderna has announced a significant expansion of vaccine production as well as the acceleration of development of a modified vaccine to take into account the new SA variant. J&J has announced

Posted in Portfolio Model Subscription

PayPal Holdings Inc. (PYPL-$296.53, NASDAQ). The Evolution of a Cryptocurrency “Interchange”.

What is the end game for the holder of cryptocurrency stored on that thumb drive in their bank safety deposit box? Anonymity is important but liquidity is paramount and that is the current issue for holders of the equity-like product

Posted in Portfolio Model Subscription

Novo Nordisk (NVO-$76, NYSE) Reports Semaglutide Results for Weight Loss. The Next Megablockbuster?

https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data https://www.clinicaltrialsarena.com/news/novo-nordisk-semaglutide-weight/ Presently, Novo Nordisk estimates that fewer than 65 million people globally, of the total assumed sample of 650 million persons that are non diabetic and have an estimated 30+ BMI (body mass index) are utilizing any sort of

Posted in Portfolio Model Subscription

Grupo Aeroporturio Del Sureste (ASR-$175, NYSE): Portfolio Weighting Increased.

Posted in Portfolio Model Subscription

Astra-Zeneca Oxford Covid-19 Vaccine Study Determines the Product is Ineffective on South African Variant.

https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36?shareType=nongift The drill-down is worse than the top-line news. With an average age of 31 for the test pool; just how many at age 31 wind up hospitalized as a result of Covid-19 contraction (yes, blah, blah, blah, there is

Posted in Portfolio Model Subscription
Recent Comments
    Archives